• Explore /
  • Poster
  • / SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist.

SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist.

Abstract Video & Slides Poster

Authors

null

Heather Metz

Silverback Therapeutics, Seattle, WA

Monica Childs , Jamie Brevik , Damion Winship , Ty Brender , Michael Comeau , Kara Moyes , Jenny Chang , Jeffrey Adamo , Ben Setter , Hengyu Xu , Li-Qun Fan , Sean Smith , Phil Tan , Robert DuBose , Yvette Latchman , Peter Baum , Valerie Odegard , Heather Metz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3110)

DOI

10.1200/JCO.2020.38.15_suppl.3110

Abstract #

3110

Poster Bd #

174

Abstract Disclosures

Similar Posters

First Author: Mark D. Pegram

First Author: Jung-Yun Lee

First Author: Sarina A. Piha-Paul

First Author: Sara A. Hurvitz